A newly listed Chinese vaccine maker has set its sights on global expansion even as it looks to regain trust in its home market after a scandal last year raised questions about the industry’s quality standards…and guess what. They are currently doing trials on a coronavirus vaccine.
CanSino Biologics jumped 59 per cent in debut trading in Hong Kong on Thursday, reflecting the best first day trading gain in the city since 2017.